In 2023, Sanofi SA’s sutimlimab (SAR-445088; formerly BIVV-020), a humanised anti-C1s monoclonal antibody, was approved for conducting clinical trials for chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neuromuscular disease, using efficacy data generated using an organ chip model (Rumsey et al., 2022). The gene discussed is C1S; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.